Across five phase III trials of SC golimumab , 639 patients received placebo and 2226 received golimumab 50 mg ( n = 1249 ) and/or 100 mg ( n = 1501 ) up to wk 160 ( patients may be included in more than one group because non-responders were allowed early escape ) ; 1179 patients were treated for 156 weeks .